Phase 3 Clinical Trial
The Phase 3 NT-501 clinical trial tests encapsulated cell-based delivery of ciliary neurotrophic factor (CNTF) in the eye as a therapy for macular telangiectasia type 2. This multicenter randomized trial is being held in Australia, Europe, the United Kingdom, and the United States. The trial is being run by Neurotech Pharmaceuticals with support from the Lowy Medical Research Institute. The Phase 3 trial follows a successful Phase 2 trial of the same therapy.
Enrollment in the Phase 3 trial will begin in phases. The first sites to enroll participants will be in the United States, starting in the fourth quarter of 2017. Sites in Europe and Australia will begin enrolling participants in 2018. Enrollment is projected to continue through 2018.
To determine eligibility for the Phase 3 trial, participants must enroll in the MacTel Project Registry. The Lowy Medical Research Institute has expanded the number of participating clinical sites. Please check our map of participating clinical sites for more information about joining the registry. Not all Registry Sites will be participating in the Phase 3 clinical trial.
If you are interested in participating in the clinical trial and would like more information, please contact us.